中國水業集團(01129.HK)上半年EBITDA增長36.09%至2.87億港元
格隆匯8月30日丨中國水業集團(01129.HK)發佈公吿,截至2021年6月30日止6個月,實現收入5.59億港元,同比增長5%;公司擁有人應占溢利6950.5萬港元,同比增長3022.42%;EBITDA 2.87億港元,同比增長36.09%;基本每股收益4.35港仙。
2021年上半年,公司擁有人應占溢利為6951萬港元,大幅增加6728萬港元,主要由於:(i)出售鷹潭市供水集團有限公司的20%股權所錄得的出售附屬公司收益;(ii)透過損益按公平值處理的金融資產的已變現及未變現收益淨額增加;及(iii)應占聯營公司溢利增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.